Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Piotr Adamowicz. (2021) Blood concentrations of synthetic cannabinoids. Clinical Toxicology 59:3, pages 246-251.
Read now
Read now
Juliana Tournebize, Valérie Gibaja & Jean-Pierre Kahn. (2017) Acute effects of synthetic cannabinoids: Update 2015. Substance Abuse 38:3, pages 344-366.
Read now
Read now
Robert J. Tait, David Caldicott, David Mountain, Simon L. Hill & Simon Lenton. (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology 54:1, pages 1-13.
Read now
Read now
G. L. Buser, R. R. Gerona, B. Z. Horowitz, K. P. Vian, M. L. Troxell, R. G. Hendrickson, D. C. Houghton, D. Rozansky, S. W. Su & R. F. Leman. (2014) Acute kidney injury associated with smoking synthetic cannabinoid. Clinical Toxicology 52:7, pages 664-673.
Read now
Read now
Articles from other publishers (61)
Soheir Ali Mohammad, Rasha Elhaddad Ali Mousa, Sahar Mohamed Gebril, Khaled Masoud Mohamed Masoud & Rania Ahmad Radwan. (2023) Toxic effects of AB-CHMINACA on liver and kidney and detection of its blood level in adult male mice. Forensic Toxicology.
Crossref
Crossref
Lakshmi Kannan. (2022) Renal manifestations of recreational drugs: A narrative review of the literature. Medicine 101:50, pages e31888.
Crossref
Crossref
Julián Portuguez Brenes, Luis E. Arroyo-Mora & Miriam Barquero-Quirós. (2022) Enzymatic inhibitive determination of AB-Fubinaca and AB-Pinaca on screen printed carbon tetratiofulvalene electrodes modified with nanoparticles and carbon nanotubes. Sensing and Bio-Sensing Research 38, pages 100515.
Crossref
Crossref
Eric Sparkes, Rochelle Boyd, Shuli Chen, Jack W. Markham, Jia Lin Luo, Tahira Foyzun, Humayra Zaman, Charlotte Fletcher, Ross Ellison, Iain S. McGregor, Marina J. Santiago, Felcia Lai, Roy R. Gerona, Mark Connor, David E. Hibbs, Elizabeth A. Cairns, Michelle Glass, Adam Ametovski & Samuel D. Banister. (2022) Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry 13.
Crossref
Crossref
Stefano D’Errico, Martina Zanon, Davide Radaelli, Monica Concato, Martina Padovano, Matteo Scopetti, Paola Frati & Vittorio Fineschi. (2022) Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers. Biomedicines 10:8, pages 1936.
Crossref
Crossref
Eric Sparkes, Elizabeth A. Cairns, Richard C. Kevin, Felcia Lai, Katharina Elisabeth Grafinger, Shuli Chen, Marie H. Deventer, Ross Ellison, Rochelle Boyd, Lewis J. Martin, Iain S. McGregor, Roy R. Gerona, David E. Hibbs, Volker Auwärter, Michelle Glass, Christophe Stove & Samuel D. Banister. (2022)
Structure–activity relationships of valine,
tert
-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA
. RSC Medicinal Chemistry 13:2, pages 156-174.
Crossref
Crossref
Haley K. Andersen & Kenneth B. Walsh. (2021) Molecular signaling of synthetic cannabinoids: Comparison of CB1 receptor and TRPV1 channel activation. European Journal of Pharmacology 907, pages 174301.
Crossref
Crossref
Monica Patel, David B. Finlay & Michelle Glass. (2021) Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists. Cellular Signalling 78, pages 109865.
Crossref
Crossref
Monica Patel, Jamie J. Manning, David B. Finlay, Jonathan A. Javitch, Samuel D. Banister, Natasha L. Grimsey & Michelle Glass. (2020) Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology 175, pages 113871.
Crossref
Crossref
Dino Luethi & Matthias E. Liechti. (2020) Designer drugs: mechanism of action and adverse effects. Archives of Toxicology 94:4, pages 1085-1133.
Crossref
Crossref
Shivani Sachdev, Kiran Vemuri, Samuel D. Banister, Mitchell Longworth, Michael Kassiou, Marina Santiago, Alexandros Makriyannis & Mark Connor. (2019)
In vitro determination of the efficacy of illicit synthetic cannabinoids at CB
1
receptors
. British Journal of Pharmacology 176:24, pages 4653-4665.
Crossref
Crossref
Elise Wouters, Jolien Walraed, Samuel D. Banister & Christophe P. Stove. (2019) Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochemical Pharmacology 169, pages 113623.
Crossref
Crossref
Elise Wouters, Lukas Mogler, Annelies Cannaert, Volker Auwärter & Christophe Stove. (2019)
Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L‐valine or L‐
tert
‐leucine
. Drug Testing and Analysis 11:8, pages 1183-1191.
Crossref
Crossref
Eva M. Mathews, Emily Jeffries, Chenen Hsieh, Glenn Jones & Julia D. Buckner. (2019) Synthetic cannabinoid use among college students. Addictive Behaviors 93, pages 219-224.
Crossref
Crossref
Laurent Karila & Amine Benyamina. 2019. Cannabis Use Disorders. Cannabis Use Disorders
169
176
.
João P. Silva, Helena Carmo & Félix Carvalho. (2018) The synthetic cannabinoid XLR-11 induces in vitro nephrotoxicity by impairment of endocannabinoid-mediated regulation of mitochondrial function homeostasis and triggering of apoptosis. Toxicology Letters 287, pages 59-69.
Crossref
Crossref
José A. Morfín & Shruti Gupta. 2018. Core Concepts in Acute Kidney Injury. Core Concepts in Acute Kidney Injury
203
219
.
Samuel D. Banister & Mark Connor. 2018. New Psychoactive Substances. New Psychoactive Substances
191
226
.
Kanaan Mansoor, Murad Kheetan, Saba Shahnawaz, Anna P. Shapiro, Eva Patton-Tackett, Larry Dial, Gary Rankin, Prasanna Santhanam, Antonios H. Tzamaloukas, Tibor Nadasdy, Joseph I. Shapiro & Zeid J. Khitan. (2017) Systematic review of nephrotoxicity of drugs of abuse, 2005–2016. BMC Nephrology 18:1.
Crossref
Crossref
Marion Gully, Élisabeth Frauger, Michel Spadari, Liselotte Pochard, Vanessa Pauly, Fanny Romain, Bertrand Gondouin, Marion Sallée, Julie Moussi-Frances, Stéphane Burtey, Bertrand Dussol, Laurent Daniel, Joëlle Micallef & Noémie Jourde-Chiche. (2017) Effets uro-néphrologiques des produits utilisés par les usagers de drogues : revue de la littérature et enquête pharmaco-épidémiologique en France et dans la région de Marseille. Néphrologie & Thérapeutique 13:6, pages 429-438.
Crossref
Crossref
Barry K. Logan, Amanda L.A. Mohr, Melissa Friscia, Alex J. Krotulski, Donna M. Papsun, Sherri L. Kacinko, Jeri D. Ropero-Miller & Marilyn A. Huestis. (2017) Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013–2016: A Review. Journal of Analytical Toxicology 41:7, pages 573-610.
Crossref
Crossref
T. W. Grim, A. J. Morales, B. F. Thomas, J. L. Wiley, G. W. Endres, S. S. Negus & A. H. Lichtman. (2017)
Apparent CB
1
Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model
. Journal of Pharmacology and Experimental Therapeutics 362:1, pages 210-218.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
Katherine E. Warren, Shirli Tay & Leana S. Wen. (2017) The Role of Public Health in Combatting Synthetic Cannabinoid Use in Adolescents. Journal of Adolescent Health 60:5, pages 483-486.
Crossref
Crossref
Brian F. Thomas, Timothy W. Lefever, Ricardo A. Cortes, Megan Grabenauer, Alexander L. Kovach, Anderson O. Cox, Purvi R. Patel, Gerald T. Pollard, Julie A. Marusich, Richard C. Kevin, Thomas F. Gamage & Jenny L. Wiley. (2017) Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences. Journal of Pharmacology and Experimental Therapeutics 361:1, pages 162-171.
Crossref
Crossref
Arani Nanavati & Leal C. Herlitz. (2017) Tubulointerstitial Injury and Drugs of Abuse. Advances in Chronic Kidney Disease 24:2, pages 80-85.
Crossref
Crossref
Alper Alp, Hakan Akdam, Banu Yılmaz Avcıoğlu & Sibel Ersan. (2017) Synthetic cannabinoids in the kidneys. Revista da Associação Médica Brasileira 63:1, pages 10-12.
Crossref
Crossref
Amandine Scocard, Amine Benyamina, Sarah Coscas & Laurent Karila. (2017) Cannabinoïdes de synthèse : une nouvelle matrice des addictions. La Presse Médicale 46:1, pages 11-22.
Crossref
Crossref
A. Helander. 2017. Handbook of Cannabis and Related Pathologies. Handbook of Cannabis and Related Pathologies
839
847
.
Ji Hyun Lee, Han Na Park, Tan-Soon Leem, Joo-hyoung Jeon, Sooyeul Cho, Jongkook Lee & Sun Young Baek. (2016) Identification of new synthetic cannabinoid analogue APINAC (adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate) with other synthetic cannabinoid MDMB(N)-Bz-F in illegal products. Forensic Toxicology 35:1, pages 45-55.
Crossref
Crossref
David M. Wood & Paul I. Dargan. 2016. Current Practice in Forensic Medicine. Current Practice in Forensic Medicine
35
46
.
Kevin G. Shanks & George S. Behonick. (2016) Death after use of the synthetic cannabinoid 5F-AMB. Forensic Science International 262, pages e21-e24.
Crossref
Crossref
Kevin G. Shanks, William Clark & George Behonick. (2016) Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA. Journal of Analytical Toxicology 40:3, pages 236-239.
Crossref
Crossref
Piotr Adamowicz. (2016) Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Science International 261, pages e5-e10.
Crossref
Crossref
Liana Fattore. (2016) Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis. Biological Psychiatry 79:7, pages 539-548.
Crossref
Crossref
Daniel Castellanos. (2016) Synthetic cannabinoids 2015: An update for pediatricians in clinical practice. World Journal of Clinical Pediatrics 5:1, pages 16.
Crossref
Crossref
Tammi Cooks, T. Keefe Davis, June Hu, Rachel Metheny, Michael Schwartz & Roy Gerona. (2014) “Smoking” guns: Answers. Pediatric Nephrology 31:1, pages 63-66.
Crossref
Crossref
Moonhee Jang, In Sook Kim, Yu Na Park, Jihyun Kim, Inhoi Han, Seungkyung Baeck, Wonkyung Yang & Hye Hyun Yoo. (2015) Determination of urinary metabolites of XLR-11 by liquid chromatography–quadrupole time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry 408:2, pages 503-516.
Crossref
Crossref
Pavlina A. Andreeva-Gateva, Vasilka H. Nankova, Violina T. Angelova & Tzvetelin N. Gatev. (2015) Synthetic cannabimimetics in Bulgaria 2010–2013. Drug and Alcohol Dependence 157, pages 200-204.
Crossref
Crossref
Vineet S. Gudsoorkar & Jose A. PerezJr.Jr.. (2015) A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure. Methodist DeBakey Cardiovascular Journal 11:3, pages 189-191.
Crossref
Crossref
Kathleen S Bonnici, Paul I Dargan & David M Wood. (2015) Novel psychoactive substances or ‘legal highs'. British Journal of Hospital Medicine 76:9, pages C130-C134.
Crossref
Crossref
C. Lovett, D. M. Wood & P. I. Dargan. (2015) Pharmacology and toxicology of the synthetic cannabinoid receptor agonistsPharmacologie et toxicologie des agonistes synthétiques des récepteurs cannabinoïdes. Réanimation 24:5, pages 527-541.
Crossref
Crossref
Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor & Michael Kassiou. (2015) Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience 6:8, pages 1445-1458.
Crossref
Crossref
Kevin G. Shanks, David Winston, John Heidingsfelder & George Behonick. (2015) Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Science International 252, pages e6-e9.
Crossref
Crossref
Benjamin R. Nordstrom, Sarah C. Akerman & Frances R. Levin. 2015. Psychiatry. Psychiatry
1458
1469
.
Jan van Amsterdam, Tibor Brunt & Wim van den Brink. (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology 29:3, pages 254-263.
Crossref
Crossref
Anne-Laure Pélissier-Alicot. (2015) Les cannabinoïdes de synthèse : épidémiologie, modalités de consommations et effets cliniques. Toxicologie Analytique et Clinique 27:1, pages 33-40.
Crossref
Crossref
Adarsh S. Gandhi, Ariane Wohlfarth, Mingshe Zhu, Shaokun Pang, Marisol Castaneto, Karl B. Scheidweiler & Marilyn A. Huestis. (2015) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liv. Drug Testing and Analysis 7:3, pages 187-198.
Crossref
Crossref
Shane M. Wilkinson, Samuel D. Banister & Michael Kassiou. (2015) Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids. Australian Journal of Chemistry 68:1, pages 4.
Crossref
Crossref
Ritva Karinen, Silja Skogstad Tuv, Elisabeth Leere Øiestad & Vigdis Vindenes. (2015) Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids. Forensic Science International 246, pages 98-103.
Crossref
Crossref
Karl B. Scheidweiler, Michael J. Y. Jarvis & Marilyn A. Huestis. (2014) Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Analytical and Bioanalytical Chemistry 407:3, pages 883-897.
Crossref
Crossref
Marisol S. Castaneto, David A. Gorelick, Nathalie A. Desrosiers, Rebecca L. Hartman, Sandrine Pirard & Marilyn A. Huestis. (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence 144, pages 12-41.
Crossref
Crossref
Asa Louis, Brianna L. Peterson & Fiona J. Couper. (2014) XLR-11 and UR-144 in Washington State and State of Alaska Driving Cases. Journal of Analytical Toxicology 38:8, pages 563-568.
Crossref
Crossref
George Behonick, Kevin G. Shanks, Dennis J. Firchau, Gagan Mathur, Charles F. Lynch, Marcus Nashelsky, David J. Jaskierny & Chady Meroueh. (2014) Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22. Journal of Analytical Toxicology 38:8, pages 559-562.
Crossref
Crossref
Michelle M WilliamsPaul J TaylorColin B PageJennifer H Martin. (2014) Clinical research in synthetic cannabinoids ‐ do we need a national approach?. Medical Journal of Australia 201:6, pages 317-319.
Crossref
Crossref
Paul Truman Harrell, Vani Nath Simmons, John Bernard Correa, Tapan Ashvin Padhya & Thomas Henry Brandon. (2014) Electronic Nicotine Delivery Systems (“E‐cigarettes”): Review of Safety and Smoking Cessation Efficacy. Otolaryngology–Head and Neck Surgery 151:3, pages 381-393.
Crossref
Crossref
Randy L. Luciano & Mark A. Perazella. (2014) Nephrotoxic effects of designer drugs: synthetic is not better!. Nature Reviews Nephrology 10:6, pages 314-324.
Crossref
Crossref
David E. Nichols & William E. Fantegrossi. 2014. The Effects of Drug Abuse on the Human Nervous System. The Effects of Drug Abuse on the Human Nervous System
575
596
.
Jamie Talan. (2013) Intensivists, Take Note. Neurology Today 13:23, pages 12.
Crossref
Crossref
Ariane Wohlfarth, Shaokun Pang, Mingshe Zhu, Adarsh S Gandhi, Karl B Scheidweiler, Hua-fen Liu & Marilyn A Huestis. (2013) First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry. Clinical Chemistry 59:11, pages 1638-1648.
Crossref
Crossref
Adarsh S. Gandhi, Mingshe Zhu, Shaokun Pang, Ariane Wohlfarth, Karl B. Scheidweiler, Hua-fen Liu & Marilyn A. Huestis. (2013) First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry. The AAPS Journal 15:4, pages 1091-1098.
Crossref
Crossref